Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

By sjmartinez • October 17, 2022

Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Oct 13:S1470-2045(22)00603-9. doi: 10.1016/S1470-2045(22)00603-9. Epub ahead of print. PMID: 36244398.

Tags: Digestive Diseases, Hematology/Oncology, Publications

Expert recommendations to standardize transcriptomic analysis in inflammatory bowel disease clinical trials

Linggi B, Azucena S, Steere B, Verstockt B, Alsoud D, Casero D, McGovern D, Chan E, Smith MI, Ungaro F, Rieder F, Aden K, Shackelton[...]

Worsening Racial and Ethnic Disparities in Colorectal Cancer Screening Rates in United States Federally Qualified Health Centers

Zhao MY, Aaronson MRM, Singh V, De Silva SR, Badiee J, May FP. Worsening Racial and Ethnic Disparities in Colorectal Cancer Screening Rates in United[...]

Understanding Microbial Mediation of the Brain-Gut Axis

Horn JA, Delgadillo DR, Mayer EA. Understanding Microbial Mediation of the Brain-Gut Axis. Gastroenterol Clin North Am. 2025 Jun;54(2):367-381. doi: 10.1016/j.gtc.2024.12.004. Epub 2025 Feb 7.[...]